Table 2

Sensitivity of primary myeloma cells to ABT-737

PatientAge, yDisease statusLD50, nM% of cell death ABT-737
64 Diagnosis > 5000 
80 Diagnosis < 100 62 
78 Diagnosis < 20 90 
69 Diagnosis 500 39 
61 Diagnosis > 5000 12 
47 Diagnosis 250 44 
71 Relapse > 5000 28 
PatientAge, yDisease statusLD50, nM% of cell death ABT-737
64 Diagnosis > 5000 
80 Diagnosis < 100 62 
78 Diagnosis < 20 90 
69 Diagnosis 500 39 
61 Diagnosis > 5000 12 
47 Diagnosis 250 44 
71 Relapse > 5000 28 

CD138+ purified myeloma cells were treated with various doses of ABT-737 during a 24-hour period. Cell viability was assessed, and the LD50 value was determined for each patient. In parallel, for each patient, we indicated the percentage of cell death upon ABT-737 treatment (100nM; 24 hours).

or Create an Account

Close Modal
Close Modal